Optimistic Buy Rating for Aclaris Therapeutics Driven by Promising Dermatology Pipeline Developments

Aclaris Therapeutics (ACRS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 28. Analyst Thomas Smith from Leerink Partners maintained a Buy rating on the stock and has a $7.00 price target.

Thomas Smith’s rating is based on several promising developments within Aclaris Therapeutics’ dermatology-focused pipeline. The company is set to initiate a Phase 2 trial of bosakitug for atopic dermatitis, leveraging previous positive open-label results to mitigate risk. This trial aims to efficiently determine bosakitug’s efficacy with a single dose level comparison against a placebo. Additionally, early data from their Chinese partner, CTTQ, has shown promising results for bosakitug in severe asthma and CRSwNP, reinforcing the potential clinical significance of its anti-TSLP potency.
Furthermore, Aclaris is anticipating topline results from a Phase 2a trial of ATI-2138 in atopic dermatitis by June 2025, with hopes for JAK-like efficacy and an improved safety profile. These results could guide future development in conditions like alopecia areata or vitiligo. The company is also progressing with a Phase 1 trial of ATI-052, with initial data expected by the end of 2026. Overall, these strategic initiatives and the anticipated data from various trials underpin Thomas Smith’s optimistic outlook and Buy rating for Aclaris Therapeutics.

In another report released on May 14, H.C. Wainwright also maintained a Buy rating on the stock with a $16.00 price target.

ACRS’s price has also changed dramatically for the past six months – from $3.820 to $1.410, which is a -63.09% drop .